MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment

On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to participate in the YL201 Phase I/II Investigators Meeting hosted by Suzhou MediLink Therapeutics Co., Ltd.

Scroll to Top